top of page

Research notes from Dr. Miyamoto

We are pleased to let you hear Dr. Sayuri Myiamoto present her preliminary work, listen to the video. There is a lot more to learn, and her lab is working on the next steps. She is publishing her novel data, we will let you know when the manuscript finishes and in the review process. A part of her work is testing ALS patients for the novel lipid markers they have identified. Although the lipid marker isn't specific for ALS, once ALS is diagnosed, it may be a prognostic marker.


We are hopeful that finding treatments that can modify (increase) this marker in a person the drugs would bring benefit to ALS patients, perhaps slowing disease progression.

14 views0 comments

Recent Posts

See All

Thymosin in the treatment of lung cancer

A new paper authored by Liu and Lu in the Frontiers in Immunology reports the Mechanism and clinical application of thymosin in the treatment of lung cancer. Thymosin is a mixture of peptides obtained

MOLECULAR MECHANISMS OF REDOX REGULATION IN INFLAMMATION

We are hopeful that TVALA will reduce p53 expression in people with ALS. There are two recent publications that give us hope. The first paper is by Maor-Nof et. al. (2022), found in Cell. The found

TVALA Fortune Journal

Pharmacological Characterization of FC-12738: A Novel Retro-Inverso Pentapeptide for Treating Neuroinflammation

bottom of page